Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000228420 | SCV000284564 | pathogenic | Neuronal ceroid lipofuscinosis 1 | 2023-10-03 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 8 of the PPT1 gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with clinical features of neuronal ceroid lipofuscinosis (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 237631). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the PPT1 protein in which other variant(s) (p.Asp267Thrfs*5) have been determined to be pathogenic (PMID: 9664077, 10649502; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Baylor Genetics | RCV000228420 | SCV004204149 | likely pathogenic | Neuronal ceroid lipofuscinosis 1 | 2024-01-04 | criteria provided, single submitter | clinical testing | |
| Counsyl | RCV000228420 | SCV000795085 | likely pathogenic | Neuronal ceroid lipofuscinosis 1 | 2019-07-12 | no assertion criteria provided | clinical testing |